PS341 inhibits hepatocellular and colorectal cancer cells through the FOXO3/CTNNB1 signaling pathway

[1]  Z. Cai,et al.  Novel variants in MLL confer to bladder cancer recurrence identified by whole-exome sequencing , 2015, Oncotarget.

[2]  S. Baldus,et al.  Expression of wingless-type mouse mammary tumor virus integration site family pathway effectors in lymphatic and hepatic metastases of patients with colorectal cancer: Associations with the primary tumor. , 2015, Oncology letters.

[3]  Hongsheng Wang,et al.  FOXO3a modulates WNT/β-catenin signaling and suppresses epithelial-to-mesenchymal transition in prostate cancer cells. , 2015, Cellular signalling.

[4]  Ziwei Wang,et al.  VGLL4 inhibits EMT in part through suppressing Wnt/β-catenin signaling pathway in gastric cancer , 2015, Medical Oncology.

[5]  Megan Scudellari.  Drug development: Try and try again , 2014, Nature.

[6]  Zhao Yang,et al.  Cytosolic carboxypeptidase CCP6 is required for megakaryopoiesis by modulating Mad2 polyglutamylation , 2014, The Journal of experimental medicine.

[7]  M. Ilyas,et al.  STAT3 paradoxically stimulates β-catenin expression but inhibits β-catenin function , 2014, International journal of experimental pathology.

[8]  Qiang Sun,et al.  Reduced expression of SOX7 in ovarian cancer: a novel tumor suppressor through the Wnt/β-catenin signaling pathway , 2014, Journal of Ovarian Research.

[9]  Hong Zhang,et al.  Interferon-stimulated Gene 15 (ISG15) is a trigger for tumorigenesis and metastasis of hepatocellular carcinoma , 2014, Oncotarget.

[10]  Samy Lamouille,et al.  Molecular mechanisms of epithelial–mesenchymal transition , 2014, Nature Reviews Molecular Cell Biology.

[11]  Sherry X. Yang,et al.  Targeting notch signaling pathway in cancer: clinical development advances and challenges. , 2014, Pharmacology & therapeutics.

[12]  A. Stein,et al.  Colorectal cancer in 2013: Towards improved drugs, combinations and patient selection , 2014, Nature Reviews Clinical Oncology.

[13]  C. Blanpain,et al.  Unravelling cancer stem cell potential , 2013, Nature Reviews Cancer.

[14]  G. Botchkina.  Colon cancer stem cells--from basic to clinical application. , 2013, Cancer letters.

[15]  J. Hurley,et al.  The molecular genetics of colorectal cancer , 2013, Frontline Gastroenterology.

[16]  G. Packham,et al.  FOXO3 expression during colorectal cancer progression: biomarker potential reflects a tumour suppressor role , 2013, British Journal of Cancer.

[17]  A. Zaniboni,et al.  Management of potentially resectable colorectal cancer liver metastases. , 2013, World journal of gastrointestinal surgery.

[18]  D. Hwang,et al.  Notch1 counteracts WNT/β-catenin signaling through chromatin modification in colorectal cancer. , 2012, The Journal of clinical investigation.

[19]  P. Brown,et al.  Hepatic stem cells and transforming growth factor β in hepatocellular carcinoma , 2012, Nature Reviews Gastroenterology &Hepatology.

[20]  J. Baselga,et al.  687 Beta-catenin Confers Resistance to PI3K and AKT Inhibitors and Subverts FOXO3a to Promote Metastasis in Colon Cancer , 2012 .

[21]  A. Anichini,et al.  Phase II study of sorafenib in patients with relapsed or refractory lymphoma , 2012, British journal of haematology.

[22]  W. Tansey,et al.  Ubiquitin and proteasomes in transcription. , 2012, Annual review of biochemistry.

[23]  Yolanda Fernández,et al.  β-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer , 2012, Nature Medicine.

[24]  D. Szydlo,et al.  An international, multicenter phase II trial of bortezomib in patients with hepatocellular carcinoma , 2012, Investigational New Drugs.

[25]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[26]  Di Chen,et al.  Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives. , 2011, Current cancer drug targets.

[27]  Neal Rosen,et al.  Targeted cancer therapies , 2011, Chinese journal of cancer.

[28]  Z. Werb,et al.  Matrix Metalloproteinases: Regulators of the Tumor Microenvironment , 2010, Cell.

[29]  C. Tiribelli,et al.  Hepatic cancer stem cells and drug resistance: Relevance in targeted therapies for hepatocellular carcinoma. , 2010, World journal of hepatology.

[30]  Xi He,et al.  Wnt/beta-catenin signaling: components, mechanisms, and diseases. , 2009, Developmental cell.

[31]  Samy Lamouille,et al.  TGF-β-induced epithelial to mesenchymal transition , 2009, Cell Research.

[32]  S. Paggi,et al.  Sorafenib in Advanced Hepatocellular Carcinoma , 2008 .

[33]  Shivendra V. Singh,et al.  Withaferin A causes FOXO3a- and Bim-dependent apoptosis and inhibits growth of human breast cancer cells in vivo. , 2008, Cancer research.

[34]  Tommer Ravid,et al.  Diversity of degradation signals in the ubiquitin–proteasome system , 2008, Nature Reviews Molecular Cell Biology.

[35]  L. Huang,et al.  Bortezomib inhibits tumor adaptation to hypoxia by stimulating the FIH-mediated repression of hypoxia-inducible factor-1. , 2008, Blood.

[36]  Takako Sasaki,et al.  The LG1-3 Tandem of Laminin α5 Harbors the Binding Sites of Lutheran/Basal Cell Adhesion Molecule and α3β1/α6β1 Integrins* , 2007, Journal of Biological Chemistry.

[37]  S. Wilhelm,et al.  Discovery and development of sorafenib: a multikinase inhibitor for treating cancer , 2006, Nature Reviews Drug Discovery.

[38]  J. Wade Harper,et al.  Drug discovery in the ubiquitin–proteasome system , 2006, Nature Reviews Drug Discovery.

[39]  M. Cavo.  Proteasome inhibitor bortezomib for the treatment of multiple myeloma , 2006, Leukemia.

[40]  Raghu Kalluri,et al.  The epithelial–mesenchymal transition: new insights in signaling, development, and disease , 2006, The Journal of cell biology.

[41]  P. Richardson,et al.  Bortezomib: proteasome inhibition as an effective anticancer therapy. , 2006, Annual review of medicine.

[42]  R. Orlowski,et al.  The proteasome and proteasome inhibitors in cancer therapy. , 2006, Annual review of pharmacology and toxicology.

[43]  H. Mackay,et al.  A Phase II Trial with Pharmacodynamic Endpoints of the Proteasome Inhibitor Bortezomib in Patients with Metastatic Colorectal Cancer , 2005, Clinical Cancer Research.

[44]  P. Richardson,et al.  Bortezomib: proteasome inhibition as an effective anticancer therapy. , 2005, Future oncology.

[45]  Frances Fiorino,et al.  Try -- and try again , 2005 .

[46]  K. Hirschi,et al.  Nutrient regulation of cell cycle progression. , 2004, Annual review of nutrition.

[47]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[48]  S. Ye,et al.  New human hepatocellular carcinoma (HCC) cell line with highly metastatic potential (MHCC97) and its expressions of the factors associated with metastasis , 1999, British Journal of Cancer.

[49]  R. Herbst,et al.  The proteasome inhibitor PS-341 in cancer therapy. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[50]  María Blanca Fernández-Viñéa.  CURRENT STATUS AND FUTURE PERSPECTIVES , 2018 .

[51]  A. Jemal,et al.  Cancer statistics, 2014 , 2014, CA: a cancer journal for clinicians.

[52]  C. Gahan,et al.  Current status and future perspectives , 2011 .

[53]  G. Collins.  The next generation. , 2006, Scientific American.

[54]  J. Hardcastle,et al.  Colorectal cancer , 1993, Europe Against Cancer European Commission Series for General Practitioners.

[55]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[56]  D. Woodfield.  Hepatocellular carcinoma. , 1986, The New Zealand medical journal.